Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Research Efforts Abound as the Role of BTK Inhibitors Continues to Evolve in CLL

October 14th 2020

Erlene  Seymour, MD, discusses BTK inhibitors and how they have shifted the standard of care for the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Davids on Selecting Between Continuous and Time-Limited Therapy in CLL

October 13th 2020

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

Venetoclax/Rituximab Maintains PFS Advantage With uMRD in Relapsed/Refractory CLL

October 13th 2020

A fixed-duration of venetoclax plus rituximab led to sustained and durable responses in patients with relapsed/refractory chronic lymphocytic leukemia who achieved undetectable minimal residual disease.

Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL

October 12th 2020

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Dr. Davids on Factors to Inform Treatment Selection in CLL

October 9th 2020

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLL

October 8th 2020

Christopher Pleyer, MD, discusses the next steps with ​the combination of ibrutinib and ​short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Dr. Pleyer on Remaining Questions With Ibrutinib Plus Short-Course Fludarabine in CLL

October 8th 2020

Christopher Pleyer, MD, discusses the safety and effectiveness of ibrutinib plus short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Dr. Seymour on the Efficacy Ibrutinib Versus Chemoimmunotherapy in Older Patients With CLL

October 7th 2020

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Dr. Davids on the Use of Chemoimmunotherapy in CLL

October 6th 2020

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

October 5th 2020

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Dr. Bhat on the Role of Targeted Therapies in CLL

October 2nd 2020

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL

September 28th 2020

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL

September 24th 2020

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL

September 24th 2020

Erlene Seymour, MD, discusses the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia.

Ibrutinib Plus Short‐Course Fludarabine Elicits Encouraging CR Rates in Previously Untreated CLL

September 23rd 2020

Christopher Pleyer, MD, discusses the phase 2 trial examining fludarabine plus ibrutinib in CLL and SLL, the next steps for the research, and where future efforts should be focused.

Dr. Seymour on the Kinase Selectivity of BTK Inhibitors in CLL

September 22nd 2020

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

September 14th 2020

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies

September 14th 2020

Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

September 11th 2020

Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.

Acalabrutinib Shows Sustained Superiority Over Standard-of-Care Regimens in Relapsed/Refractory CLL

September 11th 2020

Acalabrutinib continued to show prolonged progression-free survival with a favorable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk features.

x